Reported results
- Net sales were $66,320,000, a decrease of 6.7% compared to $71,104,000 in the prior year quarter
- Net earnings attributable to Kewaunee Scientific Corporation were $1,706,000 compared to $3,093,000 in the prior year quarter
- Diluted earnings per share were $0.58 compared to $1.04 in the prior year quarter
- Non-GAAP EBITDA was $4,525,000 compared to $6,320,000 in the prior year quarter
- International segment net earnings increased 23.5% to $794,000 from $643,000 despite lower sales; International segment non-GAAP EBITDA increased 13.9% to $1,202,000 from $1,055,000
- Order backlog increased to $169,0 million on July 31, 2026 from $165.9 million on April 30, 2026
Notes
The Company settled specific long-term incentive awards in cash rather than shares, resulting in incremental compensation expense in the corporate segment that is not expected to recur. The Domestic reportable segment was renamed to Lab Products Group (LPG) effective fiscal year 2026 with no impact on composition or prior results.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-09-09 (8-K, Item 2.02). Read the original filing on sec.gov.
